Home » Newsletters » BioWorld Science

BioWorld Science

April 13, 2012

View Archived Issues

New vaccine shows promise to treat drug addiction

Santaris Pharma identifies new candidate gene therapies for cancer

Novel antibacterials presented by MicuRx Pharmaceuticals

U.S. university patents new histone demethylase inhibitors

Anacor develops novel antibacterial and antimycobacterial agents

New potential therapies for HIV infection reported by Roche

Investigation at Novartis yields novel ENaC antagonists

Novel PFK/FBPase inhibitors divulged by Kancera

Zannan and AB Pharma develop novel highly potent HCV NS3/NS4A inhibitor

Small ApoA-I mimetic is atheroprotective and can be used to image atherosclerotic plaques

New potential oral cancer therapy developed in Korea

Novel thiazolidinediones created in Brazil

Promising first clinical results reported on Affimed TandAb

Veles Pharma prepares innovative drugs for launch

Effective antiviral biosimilar immunotherapy produced by iBioLaunch technology

Arteriocyte obtains FDA clearance for compartment syndrome trial

Joint research for metabolic disease therapies advances

Bayer HealthCare submits new MAA for Xarelto

Agreement seeks to develop companion diagnostic for Adcetris

Novel anti-infectives disclosed by State University of New Jersey

AnGes and BioLeaders enter agreement on oral vaccine for hypertension

Alchemia provides update on pivotal HA-irinotecan trial

AstraZeneca and DNDi enter drug screening collaboration

Shire signs new acquisition agreement

OPKO Health kicks off phase III program for rolapitant

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...